Machine learning for determining lateral flow device results for testing of SARS-CoV-2 infection in asymptomatic populations

Cell Rep Med. 2022 Oct 18;3(10):100784. doi: 10.1016/j.xcrm.2022.100784. Epub 2022 Sep 27.

Abstract

Rapid antigen tests in the form of lateral flow devices (LFDs) allow testing of a large population for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To reduce the variability in device interpretation, we show the design and testing of an artifical intelligence (AI) algorithm based on machine learning. The machine learning (ML) algorithm is trained on a combination of artificially hybridized LFDs and LFD data linked to quantitative real-time PCR results. Participants are recruited from assisted test sites (ATSs) and health care workers undertaking self-testing, and images are analyzed using the ML algorithm. A panel of trained clinicians is used to resolve discrepancies. In total, 115,316 images are returned. In the ATS substudy, sensitivity increased from 92.08% to 97.6% and specificity from 99.85% to 99.99%. In the self-read substudy, sensitivity increased from 16.00% to 100% and specificity from 99.15% to 99.40%. An ML-based classifier of LFD results outperforms human reads in assisted testing sites and self-reading.

Keywords: AI; COVID-19; lateral flow device; machine learning.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Testing
  • COVID-19* / diagnosis
  • Humans
  • Machine Learning
  • SARS-CoV-2 / genetics
  • Sensitivity and Specificity

Associated data

  • ISRCTN/ISRCTN30075312